
Research News
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
The emerging therapy improved vision for some participants in an earlier clinical trial.
-
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
-
Foundation Fighting Blindness Announces Over $9 Million in New Research Awards for FY2025
The Foundation Fighting Blindness is proud to announce the funding of 16 innovative research projects in Fiscal Year 2025, totaling over $9 million in new grants.
-
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
On behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial
Susvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
The therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
The company plans to complete BLA submission in early 2026.